CAPTRUST Financial Advisors
SCNI

CAPTRUST Financial Advisors’s Scinai Immunotherapeutics SCNI Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10
Closed -$1K – 3688
2022
Q2 		$1K Hold
10
– – ﹤0.01% 4735
2022
Q1 		$2K Hold
10
– – ﹤0.01% 4536
2021
Q4 		$2K Hold
10
– – ﹤0.01% 4441
2021
Q3 		$2K Sell
10
-2
-17% -$513 ﹤0.01% 4296
2021
Q2 		$3K Hold
12
– – ﹤0.01% 4055
2021
Q1 		$5K Hold
12
– – ﹤0.01% 3745
2020
Q4 		$3K Hold
12
– – ﹤0.01% 3030
2020
Q3 		$47K Buy
+12
New +$46.1K ﹤0.01% 1657

Other funds holding SCNI

Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.05B AUM 19.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

CAPTRUST Financial Advisors's SCNI Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Scinai Immunotherapeutics (SCNI) in Q3 2022, closing a stake of 10 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in SCNI in Q3 2020 and held it in 8 quarters. The position peaked at $47K in Q3 2020. 12 funds tracked by Wall St. Rank hold SCNI as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Scinai Immunotherapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 10 Scinai Immunotherapeutics shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Scinai Immunotherapeutics in Q3 2020 and held it in 8 quarters.
  • CAPTRUST Financial Advisors's Scinai Immunotherapeutics position peaked at $47K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.